Miles Prince retweeted
Congratulations to Dr Josh Tobin @JwdTobin from @MaterResearch Institute-The University of Queensland on being awarded the Snowdome Foundation #Haematology Fellowship. Dr Tobin aims to improve outcomes for #follicularlymphoma patients.
#QueenslandUniversity
Early days but always good to see hope! dgalerts.docguide.com/robust…
2
Miles Prince retweeted
It's World Blood Donor Day this Sunday, and Australians are being urged to donate to help buy more time for patients in need. #TDE7
Calls For Blood Donors
Miles Prince retweeted
Outstanding news today for myeloma patients: FDA approves subcutaneous Daratumumab, DARZALEX FASPRO (daratumumab & hyaluronidase-fihj). Fixed-dose injection given in 3 to 5 minutes. Convenient, safe, effective! #mmsm @theMMRF @IMFmyeloma globenewswire.com/news-relea…
Join me in stopping the spread of COVID-19! Download COVIDSafe, an app from the Australian Government. #COVID19
#coronavirusaustralia #stayhomesavelives covidsafe.gov.au
Miles Prince retweeted
Pretty frustrating to see so much misunderstanding with the antimalarial drugs chloroquine and hydroxychloroquine (C/HC) as presented by politicians and the media. The nuances, which are critical, are lost. My short primer on this.
The "skinny" on C/HQ
1/x
#COVID19
Miles Prince retweeted
I intubated my colleague today, a young, healthy ER doc like me. This is what I learned...
Miles Prince retweeted
WATCH 🎥 MRD in #myeloma: Can maintenance with lenalidomide increase MRD-negativity rates? The @MM_Hub spoke to @DrOlaLandgren at the #ASH19 meeting about the latest data from a phase II trial investigating lenalidomide as maintenance therapy: buff.ly/2YXMUHI #mmMRD
Miles Prince retweeted
In 2020, we'll celebrate 100 years of care.
As we celebrate our centenary, we'll reflect on our past, continue our commitment to care into the future & recognise you, our community, for helping us reach this milestone #Epworth100
Miles Prince retweeted
🎥 @StefanoLuminari from @UNIMORE_univ discusses the need for use of geriatric assessment tools to guide treatment decisions for elderly patients with DLBCL and comments on such tools presented during ASH 2019. Also available in Italian. buff.ly/36Gk5Cc #ASH19 #lymsm
Miles Prince retweeted
CONGRESS | #IMW2019 | @DrOlaLandgren presents results of a phase 1b study of once-weekly carfilzomib plus Rd (KRd) in patients with NDMM. KRd (56mg/m^2) feasible and active: response rates comparable to twice weekly dosing in frontline setting. Further evaluations required #mmsm – at Boston, MA
Miles Prince retweeted
CONGRESS | #SOHO2019 | @DrJulieVose from @UNMC talks about new frontline regimens in T-cell lymphoma. #lymsm @lymphomahub
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival | BioSpace biospace.com/article/release…
Miles Prince retweeted
Even as recently as the 1960s, the five-year survival rate for leukemia was 14%. By 2010, it had increased to 61%. hubs.ly/H0kJQ4M0
Miles Prince retweeted
CONGRESS | #IMW2019 | A pleasure to be welcomed by Boston Mayor @marty_walsh. He spoke about the importance of cancer research and care, and his own experience of having Burkitt lymphoma as a child #mmsm – at Boston, MA





























